AI English summary of an SEC filing — figures as filed
Pfizer PFEPfizer said total revenues for Q3 2025 were $16.7 billion, a decrease of $1.0 billion (6%) from $17.7 billion in Q3 2024, with a favorable foreign exchange impact of $203 million (1%).
Key points
AI summaryPfizer said total revenues for Q3 2025 were $16.7 billion, a decrease of $1.0 billion (6%) from $17.7 billion in Q3 2024, with a favorable foreign exchange impact of $203 million (1%).
The company cited declines in Paxlovid and Comirnaty as the primary drivers of the operational decrease of $1.3 billion (7%) for Q3, attributing this to lower infection rates affecting Paxlovid demand and a narrower COVID-19 vaccine recommendation in the U.S. that reduced the eligible population for Comirnaty. It said increases in Eliquis, the Vyndaqel family and Nurtec ODT/Vydura partially offset this decline.
Pfizer announced in September 2025 that it entered into a definitive agreement to acquire Metsera for $47.50 per share in cash, representing an enterprise value of approximately $4.9 billion. The agreement includes a non-transferable contingent value right entitling holders to potential additional payments of up to $22.50 per share in cash.
The company said it filed lawsuits against Metsera, Novo Nordisk and related parties in October 2025 and November relating to a competing proposal to acquire Metsera made by Novo Nordisk on October 25.
Key figures
Quarter ended September 28, 2025
- Revenue
- $16.7B
- Net income
- $3.5B
- EPS
- $0.62
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q3 2025 Total Revenues $16.7 billion
Pfizer said total revenues for Q3 2025 were $16.7 billion, a decrease of $1.0 billion (6%) from $17.7 billion in Q3 2024, with a favorable foreign exchange impact of $203 million (1%).
Source · Based on the MD&A text of the filing
Q3 Operational Revenue Decline Drivers
The company cited declines in Paxlovid and Comirnaty as the primary drivers of the operational decrease of $1.3 billion (7%) for Q3, attributing this to lower infection rates affecting Paxlovid demand and a narrower COVID-19 vaccine recommendation in the U.S. that reduced the eligible population for Comirnaty. It said increases in Eliquis, the Vyndaqel family and Nurtec ODT/Vydura partially offset this decline.
Source · Based on the MD&A text of the filing
Metsera Acquisition Agreement Terms
Pfizer announced in September 2025 that it entered into a definitive agreement to acquire Metsera for $47.50 per share in cash, representing an enterprise value of approximately $4.9 billion. The agreement includes a non-transferable contingent value right entitling holders to potential additional payments of up to $22.50 per share in cash.
Source · Based on the MD&A text of the filing
Metsera-Related Litigation
The company said it filed lawsuits against Metsera, Novo Nordisk and related parties in October 2025 and November relating to a competing proposal to acquire Metsera made by Novo Nordisk on October 25.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…